Related references
Note: Only part of the references are listed.The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia
Sahra Ali et al.
ONCOLOGIST (2019)
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling
Jennifer E. Hibma et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2018)
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
ONCOLOGIST (2018)
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
Jeffrey Baron et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Share Paper
